Category Archives: Business and Investments

Latest From Business and Investments

Kinase Drug Development – Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last decade, but when we take a look at recent approvals and NDA filings there seems to be a strengthening of the field. There are now 16 kinase inhibitors that have been approved and five seeking regulatory approval in the next few months. The last two years in particular has been a boom for the KIs, with seven approvals, three of which target Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum: The New Kids on the Biotech Block

desert

Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off the 11th Annual BIO Investor Forum and focused on non-traditional early-stage investors and deal structures. Moderated by Jeron Eaves, a senior practice executive with Campbell Alliance, the panel highlighted companies that have secured financing from creative sources, like patient advocacy groups and venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How does the NBI perform in the last quarter of the year?

YTD-10-08-2012

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months of the year, or underperform? The NBI tends to be up in the 4th quarter, but a lot of that has to do with the overall market, not the biotechs. Here are the returns for the last quarter of the year for the last 20 years: (source: Factset) When looking directly at overall performance, biotech and the broader market have had good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

deborah

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

#BIF2012 Company Snapshot: Chimerix

Chimerix

Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,